Semaglutide

Semaglutide/Glycine/B12

STARTING AT

Per Vial

Semaglutide/Glycine/B12 is an injectable medication that helps regulate blood sugar, reduce appetite, and lower inflammation. It works by activating a key receptor in the body leading to better glucose control and weight loss.

STARTING AT

Per Vial

ACTIVE INGREDIENTS
Semaglutide
GLP-1 (glucagon-like peptide-1) receptor agonist
Glycine
An amino acid to help support muscle preservation throughout weight loss
Cyanocobalamin (Vitamin B12)
Included for its potential role in easing nausea
HOW TO USE
Suggested Dosing
Injections should be administered subcutaneously (under the skin) one time weekly. Dosing typically begins at a lower dose, suggested initiation of 4 units (0.04 mL) weekly for the first 4 weeks, then escalates according to a titration schedule:
Weeks 1-4: Inject 4 units (0.04 mL) one time per week
Weeks 5-8: Inject 8 units (0.08 mL) one time per week
Weeks 9-12: Inject 18 units (0.18 mL) one time per week
Weeks 13-16: Inject 30 units (0.3 mL) one time per week
Week 16+: Inject 44 units (0.44 mL) one time per week
Dosing may deviate from this pattern to accommodate patient-specific needs.
DISCLAIMER
This compounded medication is only available when the commercially available product is unavailable or when a prescriber determines that there is a clinically significant difference for the patient.

Medicine Information

Potential Benefits

Decreases appetite and reduces cravings
Promotes weight loss
Lowers A1C levels (a marker of blood sugar control)
Improves cardiometabolic health measures
Enhances insulin sensitivity

Treatment Protocol

The medication is not insulin.
Dose adjustments should aim for the lowest appropriate dose to limit side effects and improve adherence.
Side effects such as nausea, constipation, acid reflux, stomach pain, vomiting, diarrhea, and injection site reactions are common.

Legal

Storage Instructions

Warnings

Contraindicated in patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndromes (MEN 2)
Not suitable for individuals with type 1 diabetes or diabetic ketoacidosis
Should not be used alongside other GLP-1 receptor medications
Gastric emptying may be delayed, requiring caution for procedures involving sedation or general anesthesia due to aspiration risk
Use caution in those with a history of diabetic retinopathy
Consult your healthcare provider if you have a history of pancreatitis, as the medication may increase risk
Serious side effects may involve hypoglycemia, kidney issues, or allergic reactions
Reports of suicidal thoughts and behaviors have been noted
Avoid use during pregnancy and breastfeeding. Discontinue two months prior to becoming pregnant.

Manufacturer Info

How It Works

Enhances glucose-dependent insulin secretion
Suppresses glucagon secretion
Slows gastric emptying
Influences brain regions involved in appetite regulation, leading to reduced hunger and caloric intake
Supports weight loss
Improves insulin sensitivity
Helps to decrease internal inflammation

F.A.Q

Q: How long does it take to see results?

A: Benefits like appetite reduction and weight loss may be observed within weeks, but individual responses vary.

Q: Can I use this with other medications?

A: It can be used with other medications, but it should not be used with other GLP-1 medications. Always inform your healthcare provider about all medications you're taking to to address possible interactions.

Q: Why is it formulated with glycine and vitamin B12?

A: Cyanocobalamin (vitamin B12) and glycine are added to support side effect management and muscle preservation.

Q: What if I miss an injection?

A: Contact your healthcare provider for guidance on missed doses.

References

1. Lexicomp Online. Semaglutide: Drug information. Lexi-Drugs database. Wolters Kluwer. Accessed May 14, 2025. https://online.lexi.com/lco/action/ doc/retrieve/docid/patch_f/6577162

2. Chao AM, Tronieri JS, Amaro A, Wadden TA. Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. Drug Des Devel Ther. 2022 Dec 29;16:4449-4461. doi: 10.2147/DDDT.S365416. PMID: 36601368; PMCID: PMC9807016.

3. Khoo TK, Lin J. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Jul 1;385(1):e4. doi: 10.1056/NEJMc2106918. PMID: 34192447.

4. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. PMID: 37952131.